Cost Effectiveness and Resource Allocation

Table 3 Outcomes at 14 days and 3 months

From: Controlling hypertension immediately post stroke: a cost utility analysis of a pilot randomised controlled trial

	N
	A	P	A	P	A-P	P-value
Mean (SE) utility
Baseline	112	59	0.892 (0.007)	0.899 (0.008)	-0.007
14 days	112	59	0.551 (0.022)	0.526 (0.035)	0.026	0.519
3 months	18	14	0.366 (0.100)	0.088 (0.060)	0.278	0.035
Mean (SE) QALYs gained
14 days	112	59	0.028 (0.0005)	0.027 (0.0007)	0.000	0.650
3 months	18	14	0.102 (0.0185)	0.054 (0.0116)	0.048	0.051
Survival n (%)
14 days	112	59	107 (95.54)	53 (89.83)	5.71%	0.148
3 months	112	59	102 (91.07)	47 (79.66)	11.41%	0.034
mRS<4 n (%)
Baseline	112	59	112 (100)	59 (100)	0.00%
14 days	112	59	44 (39.29)	24 (40.68)	-1.39%	0.860
3 months	18	14	8 (44.44)	1 (7.14)	37.30%	0.020

*Based on mapped mRS scores
**t-test for continuous variables, χ² for proportions
A = active, P = placebo. Note figures vary from those reported in Table 1 due to numbers of observations included (see Figure 1).

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com